Document is current

Article History

Received: 17 November 2025

Accepted: 15 December 2025

First Online: 2 January 2026

Declarations

:

: Paul Laffont-Lozes has received support for attending meetings and/or travel from Mundipharma. Albert Sotto has received consulting fees from Besins Healthcare and Karo Pharma, support for attending meetings and/or travel from Pfizer and MSD and participates free of charge on advisory boards of Biofilm Control and CTX Laboratory. Paul Loubet has received personal consulting fees, payment or honoraria, and non-financial support for lectures, presentations, speakers’ bureaus, or educational events from AstraZeneca, BioMérieux, GSK, Gilead, Janssen, MSD, Moderna, Pfizer, Sanofi, ViiV Healthcare, Servier, Tillotts Pharma and Seqirus. Alix Pantel received speaker and consulting fees from bioMérieux and Shionogi, and support for attending meetings and/or travel from bioMérieux, MSD, Shionogi and Pfizer. Romaric Larcher has received consulting fees from MSD, payment or honoraria for lectures, presentations, speakers’ bureaus or educational events from bioMérieux, MSD, Pfizer and Shionogi, and support for attending meetings and/or travel from bioMérieux, MSD, Pfizer and Shionogi. All other authors (Fanny Villa and Céline Mory) declare that they have no conflict of interest.

: Ethical approval was not required by the local ethics committee for this case report as it describes the patient’s standard clinical management (continuous administration of β-lactam and TDM) in our institution. The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments. The patient provided written informed consent to participate in the study. The patient provided written informed consent for the publication of this report.